These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 32014881)

  • 1. Dissemination of trial results to participants in phase III pragmatic clinical trials: an audit of trial investigators intentions.
    Raza MZ; Bruhn H; Gillies K
    BMJ Open; 2020 Feb; 10(1):e035730. PubMed ID: 32014881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Registration audit of clinical trials given a favourable opinion by UK research ethics committees.
    Denneny C; Bourne S; Kolstoe SE
    BMJ Open; 2019 Feb; 9(2):e026840. PubMed ID: 30796130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A limited number of medicines pragmatic trials had potential for waived informed consent following the 2016 CIOMS ethical guidelines.
    Dal-Ré R; Avendaño-Solà C; de Boer A; James SK; Rosendaal FR; Stephens R; Ioannidis JPA
    J Clin Epidemiol; 2019 Oct; 114():60-71. PubMed ID: 31212001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies.
    Dundar Y; Dodd S; Dickson R; Walley T; Haycox A; Williamson PR
    Health Technol Assess; 2006 Feb; 10(5):iii-iv, ix-145. PubMed ID: 16487455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical trials in general practice: the first 100 protocols. An audit by the clinical research ethics committee of the Royal College of General Practitioners.
    Wise P; Drury M
    BMJ; 1996 Nov; 313(7067):1245-8. PubMed ID: 8939118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cluster over individual randomization: are study design choices appropriately justified? Review of a random sample of trials.
    Taljaard M; Goldstein CE; Giraudeau B; Nicholls SG; Carroll K; Hey SP; Brehaut JC; Jairath V; London AJ; Eldridge SM; Grimshaw JM; Fergusson DA; Weijer C
    Clin Trials; 2020 Jun; 17(3):253-263. PubMed ID: 32367741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency and format of clinical trial results dissemination to patients: a survey of authors of trials indexed in PubMed.
    Schroter S; Price A; Malički M; Richards T; Clarke M
    BMJ Open; 2019 Oct; 9(10):e032701. PubMed ID: 31636111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using routinely recorded data in the UK to assess outcomes in a randomised controlled trial: The Trials of Access.
    Powell GA; Bonnett LJ; Tudur-Smith C; Hughes DA; Williamson PR; Marson AG
    Trials; 2017 Aug; 18(1):389. PubMed ID: 28835254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of articles directly related to randomized trials finds poor protocol availability and inconsistent linking of articles.
    Sender D; Clark J; Hoffmann TC
    J Clin Epidemiol; 2020 Aug; 124():69-74. PubMed ID: 32360508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Data monitoring committees for pragmatic clinical trials.
    Ellenberg SS; Culbertson R; Gillen DL; Goodman S; Schrandt S; Zirkle M
    Clin Trials; 2015 Oct; 12(5):530-6. PubMed ID: 26374679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reporting of Randomized Trials in Common Cancers in the Lay Media.
    Ribnikar D; Goldvaser H; Ocana A; Templeton AJ; Seruga B; Amir E
    Oncology; 2018; 94(2):65-71. PubMed ID: 29151109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining the level of data sharing, and number of publications, from research databases that have been given a favourable opinion by UK research ethics committees.
    Trace S; Bracher M; Kolstoe SE
    BMJ Open; 2020 Sep; 10(9):e039756. PubMed ID: 32998929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between pacifier use and breast-feeding, sudden infant death syndrome, infection and dental malocclusion.
    Callaghan A; Kendall G; Lock C; Mahony A; Payne J; Verrier L
    JBI Libr Syst Rev; 2005; 3(6):1-33. PubMed ID: 27819973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Could phase 3 medicine trials be tagged as pragmatic? A case study: The Salford COPD trial.
    Dal-Ré R
    J Eval Clin Pract; 2018 Feb; 24(1):258-261. PubMed ID: 28685913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between publicly accessible publications, registries, and protocols of phase III trials indicated persistence of selective outcome reporting.
    Zhang S; Liang F; Li W
    J Clin Epidemiol; 2017 Nov; 91():87-94. PubMed ID: 28757260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of treatment effect from randomised controlled phase II trials and subsequent phase III trials using identical regimens in the same treatment setting.
    Liang F; Wu Z; Mo M; Zhou C; Shen J; Wang Z; Zheng Y
    Eur J Cancer; 2019 Nov; 121():19-28. PubMed ID: 31526874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing a framework for the ethical design and conduct of pragmatic trials in healthcare: a mixed methods research protocol.
    Taljaard M; Weijer C; Grimshaw JM; Ali A; Brehaut JC; Campbell MK; Carroll K; Edwards S; Eldridge S; Forrest CB; Giraudeau B; Goldstein CE; Graham ID; Hemming K; Hey SP; Horn AR; Jairath V; Klassen TP; London AJ; Marlin S; Marshall JC; McIntyre L; McKenzie JE; Nicholls SG; Alison Paprica P; Zwarenstein M; Fergusson DA
    Trials; 2018 Sep; 19(1):525. PubMed ID: 30261933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reporting of ethical requirements in phase III surgical trials.
    Bridoux V; Schwarz L; Moutel G; Michot F; Herve C; Tuech JJ
    J Med Ethics; 2014 Oct; 40(10):687-90. PubMed ID: 23959837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The AMBER care bundle for hospital inpatients with uncertain recovery nearing the end of life: the ImproveCare feasibility cluster RCT.
    Koffman J; Yorganci E; Murtagh F; Yi D; Gao W; Barclay S; Pickles A; Higginson I; Johnson H; Wilson R; Bailey S; Ewart C; Evans C
    Health Technol Assess; 2019 Oct; 23(55):1-150. PubMed ID: 31594555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.